- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 20-F Annual report (foreign)
- 1.2 EX-1.2
- 1.3 EX-1.3
- 2.2 EX-2.2
- 2.3 EX-2.3
- 4.26 EX-4.26
- 4.27 EX-4.27
- 4.28 EX-4.28
- 4.29 EX-4.29
- 4.30 EX-4.30
- 4.31 EX-4.31
- 4.32 EX-4.32
- 4.33 EX-4.33
- 4.34 EX-4.34
- 4.35 EX-4.35
- 4.36 EX-4.36
- 4.37 EX-4.37
- 4.38 EX-4.38
- 4.39 EX-4.39
- 4.40 EX-4.40
- 4.41 EX-4.41
- 4.42 EX-4.42
- 4.43 EX-4.43
- 4.44 EX-4.44
- 4.45 EX-4.45
- 4.46 EX-4.46
- 4.47 EX-4.47
- 8 EX-8
- 11.1 EX-11.1
- 11.2 EX-11.2
- 12.1 EX-12.1
- 12.2 EX-12.2
- 13.1 EX-13.1
- 13.2 EX-13.2
- 15 EX-15
- 17 EX-17
- 97.1 EX-97.1
- Download Excel data file
- View Excel data file
Exhibit 15
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors
Theratechnologies Inc.
We consent to the incorporation by reference in the Registration Statement (No. 333-276196) on Form F-3 of Theratechnologies Inc. of our report dated February 20, 2024 on the consolidated financial statements of Theratechnologies Inc (the “Entity”) which comprise the consolidated financial position as of November 30, 2023 and 2022, the related consolidated statements of net loss and comprehensive loss, changes in equity and cash flows for each of the years in the three-year period ended November 30, 2023, and the related notes, which is included in the Annual Report on Form 20-F of the Entity for the fiscal year ended November 30, 2023.
/s/ KPMG LLP
February 21, 2024
Montréal, Canada